Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
暂无分享,去创建一个
John Wikstrand | Johan Herlitz | Rainer Dietz | Jirí Vítovec | András Jánosi | Stephen S. Gottlieb | Åke Hjalmarson | Lars Gullestad | B. Fagerberg | S. Ball | A. Jánosi | G. Thorgeirsson | S. Gottlieb | P. Deedwania | R. Dietz | R. Dietz | J. Herlitz | F. Waagstein | H. Wedel | J. Kjekshus | P. Dunselman | S. Goldstein | L. Gullestad | J. Aldershvile | A. Hjalmarson | J. Wikstrand | D. E. Allaf | J. Vítovec | M. Halinen | K. Neuhaus | J. Kuch | P. Rickenbacher | Gudmundur Thorgeirsson | Finn Waagstein | S. Ball | Peter Rickenbacher | John Kjekshus | Karl-Ludwig Neuhaus | Sidney Goldstein Björn Fagerberg | Hans Wredel | Dia El Allaf | Jan Aldershivile | Matti Halinen | Peter H.J.M. Dunselman | Jerzy Kuch | Stephen G. Ball | S. B. Fagerberg | Hans Wredel | Jan Aldershivile | Å. Hjalmarson | K. Neuhaus | P. H. Dunselman
[1] K. Bailey,et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. , 1999, Archives of internal medicine.
[2] A. Hall,et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. , 1996, European heart journal.
[3] J. Herlitz. Rationale, design, and organisation of the metoprolol CR/XL randomized trial in heart failure (MERIT-HF) , 1997 .
[4] T. Hedner,et al. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.
[5] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[6] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[7] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[8] Thomas D. Giles,et al. Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .
[9] S. Gottlieb,et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.
[10] J. A. Bowers,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.
[11] S. Yusuf,et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.
[12] Milton Packer,et al. Safety and efficacy of carvedilol in severe heart failure , 1997 .
[13] J. Cohn,et al. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.
[14] B. Andersson. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial , 1998, The Lancet.
[15] Y Wang,et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.
[16] D A Bloch,et al. Capturing the patient's view of change as a clinical outcome measure. , 1999, JAMA.